Aims to increase sales to more than £300m by 2013
Aesica Pharmaceuticals has been named number three in the 2011 Sunday Times Deloitte Buyout Track 100 following the company’s most successful year since it was formed in 2004.
The Deloitte list ranks the UK’s top private equity backed companies with the fastest growing profits. This is the second year in which Aesica has featured in the list, climbing 47 places from last year’s number 50 position.
Aesica’s profit increased by 106% to £14.7m in 2009, up from £3.5m in 2007.
Aesica’s chief executive Robert Hardy, said: ‘We have had a very clear strategy in place for expansion over the past 12 months starting with the acquisition of R5 Pharmaceuticals in Nottingham in June 2010, followed by the acquisition of three European manufacturing sites from UCB, which are due to complete shortly. The European acquisitions, which include a long-term strategic partnership with UCB, will result in our workforce almost doubling to approximately 1,300 people, which will have a significant impact on revenue in 2011.’
Aesica has also recruited new business development managers for San Diego and New York in preparation for future expansion across America.
By 2013 the company expects sales to reach in excess of £300m.
Aesica supplies contract development and contract manufacturing services for formulated products and active pharmaceutical ingredients to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.